Neumann and Baumgardner in Health Affairs: Balance Needed in Cost-Effectivness Analysis
In a new blog commentary for Health Affairs, PHE’s Peter Neumann and James Baumgardner examine the reasons why application of CEA technologies across different types of healthcare interventions are imbalanced, and suggest some possible ways in which the policies of government and private entities might change to address the issue.
To read the complete blog, please click here.
By: Jason Shafrin, PhD Sr. Director, Policy and Economics and Jacki Chou, MPL Senior Director, Policy and Economics The recent announcement that CVS Caremark will use value-based metrics to inform formulary design at first appears a step in the right direction. However, using value measurements from a single nongovernmental organization—the Institute for Clinical and Economic Review (ICER)—based on a limited picture of treatment value may be problematic. Using this single assessment of value in an effort solely to exclude drugs from a major insurance formulary is even more worrisome and fails to recognize the heterogeneity in patient clinical needs and preferences.